MESO Mesoblast Limited Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

MESO [NASD]

Mesoblast Limited

Healthcare | Biotechnology | Australia

statements

Index	-	P/E	-	EPS (ttm)	-0.74	Insider Own	-	Shs Outstand	105.76M	Perf Week	11.92%
Market Cap	2.27B	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-	Shs Float	101.89M	Perf Month	4.63%
Income	-77.90M	PEG	-	EPS next Q	-0.23	Inst Own	2.50%	Short Float	2.61%	Perf Quarter	73.42%
Sales	32.20M	P/S	70.56	EPS this Y	18.90%	Inst Trans	17.30%	Short Ratio	2.45	Perf Half Y	428.26%
Book/sh	5.19	P/B	3.75	EPS next Y	98.20%	ROA	-11.40%	Target Price	21.60	Perf Year	186.73%
Cash/sh	1.11	P/C	17.58	EPS next 5Y	48.80%	ROE	-15.50%	52W Range	3.12 - 21.28	Perf YTD	163.77%
Dividend	-	P/FCF	-	EPS past 5Y	13.10%	ROI	-9.80%	52W High	-11.70%	Beta	3.55
Dividend %	-	Quick Ratio	1.50	Sales past 5Y	10.20%	Gross Margin	21.30%	52W Low	502.22%	ATR	0.96
Employees	102	Current Ratio	1.50	Sales Q/Q	-65.00%	Oper. Margin	-	RSI (14)	57.75	Volatility	4.17% 5.10%
Optionable	Yes	Debt/Eq	0.18	EPS Q/Q	-48.50%	Profit Margin	-	Rel Volume	1.05	Prev Close	19.44
Shortable	Yes	LT Debt/Eq	0.12	Earnings	Aug 26 AMC	Payout	-	Avg Volume	1.09M	Price	18.79
Recom	1.80	SMA20	6.50%	SMA50	15.39%	SMA200	71.68%	Volume	115,261	Change	-3.34%

Aug-14-20

Reiterated

Maxim Group

Buy

$16 → $22

May-28-20

Reiterated

H.C. Wainwright

Buy

$14 → $21

Jan-31-19

Resumed

H.C. Wainwright

Buy

$6.50

Mar-22-18

Downgrade

Credit Suisse

Neutral → Underperform

Feb-28-18

Reiterated

Cantor Fitzgerald

Buy

$20 → $23

Aug-31-17

Initiated

Oppenheimer

Outperform

$16

Jun-08-17

Initiated

Cantor Fitzgerald

Buy

Sep-17-20 10:11AM	3 Strong Buy Healthcare Stocks With Major Catalysts Approaching TipRanks
Sep-15-20 06:00AM	Mesoblast Wins 2020 Fierce Biotech Innovation of the Year Award for remestemcel-L GlobeNewswire
Sep-10-20 09:04AM	Implied Volatility Surging for Mesoblast (MESO) Stock Options Zacks
Sep-04-20 06:00AM	Data Safety Monitoring Board Recommends Continuation of Remestemcel-L Phase 3 Trial in COVID-19 Patients With Acute Respiratory Distress Syndrome GlobeNewswire -6.23%
Sep-02-20 06:00AM	Mesoblast Receives Ethics Approval to Treat COVID-19 Patients in Australia GlobeNewswire
03:31AM	Mesoblasts Late-Stage Covid-19 Trial Secures Ethics Approval In Australia SmarterAnalyst
Aug-26-20 07:45PM	ROSEN, A LEADING NATIONAL LAW FIRM, Continues Investigation of Securities Claims Against Mesoblast Limited; Encourages Investors with Losses in Excess of $100K to Contact the Firm MESO Business Wire
06:53PM	Mesoblast Reports Substantial Operational Progress and Financial Results for the Year Ended June 30, 2020 GlobeNewswire
Aug-25-20 08:37PM	Mesoblast 2020 Full Year Financial Results Webcast GlobeNewswire -5.56%
Aug-19-20 08:00AM	Mesoblast Limited Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire -6.03%
Aug-18-20 05:30PM	EQUITY ALERT: ROSEN, A TRUSTED AND TOP RANKED FIRM, Announces Investigation of Securities Claims Against Mesoblast Limited; Encourages Investors with Losses in Excess of $100K to Contact the Firm MESO GlobeNewswire
11:16AM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
Aug-17-20 04:00PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Mesoblast Limited (MESO) Investigation ACCESSWIRE +10.79%
Aug-16-20 09:55PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
02:47PM	MESO EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Mesoblast Limited MESO Business Wire
Aug-14-20 04:22PM	5 Stock Gainers for Friday: Dillard's, Intrepid Potash, Suzano SA TheStreet.com +51.40%
01:53PM	Mesoblast Gets Favorable Votes From FDA Committee for Ryoncil Zacks
11:02AM	Why Mesoblast's Stock is Trading Higher Today Benzinga
06:00AM	U.S. FDA Advisory Committee Votes Nine to One in Favor of Remestemcel-L (Ryoncil) for Efficacy in Children With Steroid-Refractory Acute Graft Versus Host Disease GlobeNewswire
Aug-13-20 09:57PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO PR Newswire
Aug-12-20 07:51AM	Mesoblast Tanks 35% Ahead Of FDA Meeting; Analyst Sees 85% Stock Upside SmarterAnalyst
Aug-11-20 02:46PM	Mesoblast Plunges as FDA Questions Cell-Therapy Manufacturing Motley Fool -34.96%
06:00AM	Update on Scheduled FDA Advisory Committee Meeting GlobeNewswire
Jul-21-20 05:33PM	FDA Advisory Committee Sets Review Date for Mesoblasts remestemcel-L in Pediatric Steroid-Refractory Acute Graft Versus Host Disease GlobeNewswire
Jul-16-20 09:32PM	Is Mesoblast Limited's (ASX:MSB) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Jul-10-20 12:18PM	Mesoblast expands compassionate use COVID-19 program Yahoo Finance Video
Jul-06-20 04:37PM	Here's Why Mesoblast Stock Rose Over 18% Today Motley Fool +9.14%
06:00AM	Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19 GlobeNewswire
Jun-01-20 06:00AM	Remestemcel-L Improves Respiratory and Functional Outcomes in Patients With Inflammatory Lung Disease GlobeNewswire
May-30-20 10:49PM	Is Mesoblast Limited (MESO) A Good Stock To Buy? Insider Monkey
May-28-20 11:00AM	Mesoblast Limited (MESO) Q3 2020 Earnings Call Transcript Motley Fool
May-27-20 05:53PM	Mesoblast Reports Strong Financial Position and Substantial Operational Progress For the Period Ended March 31, 2020 GlobeNewswire
May-26-20 06:00AM	Mesoblast to Host Analyst Call on Financial Results for Period Ended March 31, 2020 GlobeNewswire +6.83%
May-25-20 07:00AM	Clinical Outcomes Using RYONCIL (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles in Biology of Blood and Marrow Transplantation GlobeNewswire
May-19-20 08:03PM	Who Has Been Buying Mesoblast Limited (ASX:MSB) Shares? Simply Wall St. -5.32%
May-13-20 02:23PM	Here's Why Mesoblast Is Soaring Today Motley Fool +6.67%
06:00AM	Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDS GlobeNewswire
May-06-20 06:00AM	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblasts Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome GlobeNewswire +7.19%
Apr-30-20 07:00AM	Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment GlobeNewswire
Apr-27-20 06:25PM	Can Mesoblasts COVID-19 Treatment Increase Survival Rate? Analyst Dives In TipRanks -24.98%
04:16PM	Shares of Mesoblast Tumbled Over 20% Today After Doubling Last Week Motley Fool
Apr-24-20 06:00AM	83% Survival in COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome Treated in New York with Mesoblasts Cell Therapy Remestemcel-L GlobeNewswire +139.53%
Apr-17-20 06:00AM	Mesoblast to Present Positive Clinical Outcomes Using Remestemcel-L in Patients With Inflammatory Lung Disease at 2020 International Society of Cell and Gene Therapy Annual Meeting GlobeNewswire
Apr-15-20 08:35AM	The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron Zacks
Apr-13-20 07:46PM	Update: Mesoblast (ASX:MSB) Stock Gained 57% In The Last Year Simply Wall St.
Apr-10-20 11:38AM	Pluristem Therapeutics Shares Jump on Covid-19 Study Results GuruFocus.com
Apr-08-20 07:15PM	MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTHS NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 GlobeNewswire
Apr-06-20 06:00AM	FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19 GlobeNewswire +46.67%
Apr-03-20 02:42AM	Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review Zacks -7.08%
Apr-01-20 06:00AM	FDA ACCEPTS MESOBLASTS BIOLOGICS LICENCE APPLICATION FOR RYONCIL AND AGREES TO PRIORITY REVIEW GlobeNewswire
Mar-30-20 06:00AM	CLINICAL OUTCOMES OF MESOBLASTS CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS GlobeNewswire +7.16%
Mar-11-20 11:06AM	Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More Zacks -19.13%
Mar-10-20 06:00AM	Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease GlobeNewswire +21.14%
Feb-28-20 07:35PM	Earnings Update: Mesoblast Limited Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St. -11.25%
Feb-26-20 04:59PM	Mesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019 GlobeNewswire
Feb-25-20 06:00AM	Mesoblast to Host Analyst Call on First Half Financial Results for Period Ended December 31, 2019 GlobeNewswire
Feb-24-20 06:00AM	Consistent Outcomes Using Ryoncil as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD GlobeNewswire -8.55%
Feb-20-20 06:00AM	Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease GlobeNewswire
Feb-03-20 06:00AM	Mesoblast Submits Completed Biologics License Application for Ryoncil to US FDA GlobeNewswire
Jan-23-20 03:26PM	Is Mesoblast Limited's (ASX:MSB) CEO Being Overpaid? Simply Wall St. +5.81%
10:18AM	Will Mesoblast Continue to Surge Higher? Zacks
Jan-20-20 09:59AM	Zacks.com featured highlights include: China Distance Education, Intellicheck, Snap and Mesoblast Zacks
Jan-17-20 09:22AM	4 Affordable Breakout Stocks for Stunning Returns Zacks +13.00%
Jan-15-20 06:00AM	Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San Francisco GlobeNewswire
Jan-09-20 08:46AM	Zacks.com featured highlights include: CNX Midstream Partners LP, Akoustis Technologies, CRH Medical, Mesoblast and Photronics Zacks
Jan-08-20 07:24AM	5 Breakout Stocks for Explosive Returns Zacks
Jan-03-20 07:19AM	Will Mesoblast Continue to Surge Higher? Zacks -6.13%
Jan-02-20 06:00AM	Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L GlobeNewswire +6.24%
Jan-01-20 05:45PM	Mesoblast Submits Clinical Efficacy and Safety Data to FDA in Rolling Biologics License Application for Remestemcel-l Benzinga
Dec-18-19 06:00AM	Data Monitoring Committee Completes Final Scheduled Review of Mesoblasts Phase 3 Trial of Revascor in Advanced Chronic Heart Failure GlobeNewswire -9.03%
Dec-17-19 06:00AM	Mesoblasts Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion GlobeNewswire +9.12%
Dec-09-19 03:24PM	Trade Alert: The Independent Non-Executive Vice Chairman Of Mesoblast Limited (ASX:MSB), William A. Burns, Has Just Spent US$60k Buying Shares Simply Wall St.
Nov-29-19 03:26PM	AU$5.73 - That's What Analysts Think Mesoblast Limited Is Worth After These Results Simply Wall St.
Nov-25-19 04:52PM	Mesoblast Finanical Results for the Quarter Ended September 30, 2019 GlobeNewswire
Nov-21-19 04:29PM	Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019 GlobeNewswire
Oct-16-19 06:17PM	Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblasts Potential First United States Allogeneic Cell Therapy GlobeNewswire
Oct-08-19 08:10AM	Top Ranked Momentum Stocks to Buy for October 8th Zacks
Oct-03-19 07:59AM	Mesoblast Completes Successful Institutional Capital Raising of A$75 Million GlobeNewswire -7.36%
Sep-25-19 09:13AM	Will Mesoblast Continue to Surge Higher? Zacks
Sep-23-19 06:00AM	The Opioid Crisis Has Upended Pain Management. Whats Next for the Industry. Barrons.com
Sep-09-19 07:40PM	Mesoblast Corporate Update: Analyst Call GlobeNewswire
07:38PM	Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain GlobeNewswire
Aug-29-19 05:50PM	Mesoblast Reports 2019 Full Year Results GlobeNewswire
Aug-27-19 06:36PM	Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019 GlobeNewswire
06:00AM	FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD GlobeNewswire
Aug-14-19 06:00AM	Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial GlobeNewswire
Aug-12-19 06:00AM	Mesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer GlobeNewswire
Jul-31-19 06:00AM	Mesoblast Quarterly Cash Flow Report GlobeNewswire
Jul-27-19 08:50PM	Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market? Simply Wall St.
Jul-25-19 06:00AM	Circulation Research Special Article Highlights Potential Of Mesoblast Cell Therapy In Treatment Of Advanced Heart Failure GlobeNewswire
Jun-28-19 12:40AM	If You Had Bought Mesoblast (ASX:MSB) Stock Five Years Ago, You'd Be Sitting On A 69% Loss, Today Simply Wall St. +5.15%
Jun-25-19 04:32PM	Why Teva Pharmaceutical Industries, Mesoblast, and New Gold Jumped Today Motley Fool +12.00%
Jun-24-19 02:16PM	Mesoblast Trades Higher After Heart Failure Cell Therapy Receives Orphan Drug Status Benzinga +6.84%
06:00AM	Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices GlobeNewswire
Jun-18-19 06:00AM	High Economic Burden in Children With Steroid Refractory Acute Graft Versus Host Disease GlobeNewswire
Jun-14-19 10:28AM	Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease GlobeNewswire
Jun-11-19 06:00AM	Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement to Use of Mesenchymal Stem Cells in Newborns With Insufficient Blood Flow to the Brain GlobeNewswire
May-30-19 07:09PM	Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019 GlobeNewswire
04:51PM	Mesoblast Starts Rolling BLA Submission for Remestemcel-L Zacks
06:00AM	Mesoblast Financial Results Webcast for Period Ended March 31, 2019 GlobeNewswire

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grunenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience